Study shows children aged 5-11 respond well to Pfizer jabs Study shows children aged 5-11 respond well to Pfizer jabs
TUESDAY, SEPTEMBER 21, 2021
Pfizer and German biotechnology firm BioNTech SE on Tuesday released results from a Phase 2/3 trial showing a favourable safety profile and robust neutralising antibody responses in children aged five to 11 using a two-dose regimen of 10µg (microgram) administered 21 days apart. This dose is smaller than the 30µg used for children above 12.